Stocktoria
Evolus, Inc. EOLS
Evolus, Inc. (EOLS) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $297.2M at a -17.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.55 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.299 |
| Retained earnings / assets | -2.927 |
| EBIT / assets | -0.145 |
| Equity / liabilities | -0.093 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| EOLS | Evolus, Inc. | 2/9 | -8.65 | — | +11.6% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | 4/9 | -11.97 | 28.3 | -15.7% |
| RIGL | RIGEL PHARMACEUTICALS INC | 5/9 | 0.31 | 2 | +64.1% |
| XERS | Xeris Biopharma Holdings, Inc. | 7/9 | -2.99 | — | +43.7% |
| AUPH | Aurinia Pharmaceuticals Inc. | 5/9 | 5.18 | 7.7 | +20.4% |
| CRMD | CorMedix Inc. | 5/9 | 3.07 | 3.8 | +617% |
| HROW | HARROW, INC. | 6/9 | 1.29 | — | +36.4% |
About Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
FAQ
Is EOLS financially healthy?
Evolus, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does EOLS pay a dividend?
No, Evolus, Inc. does not currently pay a dividend.
How profitable is EOLS?
In FY2025, Evolus, Inc. had a net margin of -17.4%.
What is the analyst price target for EOLS?
The average Wall-Street price target for Evolus, Inc. is $14.67, about 80.6% above the recent price, from 6 analysts (consensus: strong buy).
Is EOLS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Evolus, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.